These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23291936)

  • 21. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.
    Bamford A; Kelleher P; Lyall H; Haston M; Zancolli M; Goldblatt D; Kampmann B
    AIDS; 2014 Sep; 28(14):2033-43. PubMed ID: 25222526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.
    Cheng A; Chang SY; Tsai MS; Su YC; Liu WC; Sun HY; Hung CC
    J Int AIDS Soc; 2016; 19(1):20631. PubMed ID: 26829360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
    Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
    J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.
    Russell FM; Balloch A; Licciardi PV; Carapetis JR; Tikoduadua L; Waqatakirewa L; Cheung YB; Mulholland EK; Tang ML
    Vaccine; 2011 Jun; 29(27):4499-506. PubMed ID: 21539882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.
    Happe M; Samuvel DJ; Ohtola JA; Korte JE; Westerink MAJ
    Vaccine; 2019 Mar; 37(12):1622-1629. PubMed ID: 30797636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.
    Zangwill KM; Greenberg DP; Chiu CY; Mendelman P; Wong VK; Chang SJ; Partridge S; Ward JI
    Vaccine; 2003 May; 21(17-18):1894-900. PubMed ID: 12706674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
    Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
    Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.
    Rose MA; Schubert R; Strnad N; Zielen S
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1216-22. PubMed ID: 16210486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy.
    Garcia Garrido HM; Schnyder JL; Haydari B; Vollaard AM; Tanck MWT; de Bree GJ; Meek B; Grobusch MP; Goorhuis A
    Int J Antimicrob Agents; 2022 Aug; 60(2):106629. PubMed ID: 35760223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
    Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
    Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
    AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal Changes in Pneumococcal Colonization in HIV-infected and HIV-uninfected Mother-Child Pairs Following Transitioning From 7-valent to 13-valent Pneumococcal Conjugate Vaccine, Soweto, South Africa.
    Nzenze SA; von Gottberg A; Shiri T; van Niekerk N; de Gouveia L; Violari A; Nunes MC; Madhi SA
    J Infect Dis; 2015 Oct; 212(7):1082-92. PubMed ID: 25784729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
    Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
    Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.